The effect of Pentoxifylline on C reactive protein level and dialysis adequacy

The effect of Pentoxifylline on C reactive protein level and dialysis adequacy in end stage renal disease patients under hemodialysis

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2013120715695N1

Enrollment

Registered

2014-01-28

Start date

2014-03-21

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: esrd. Condition 2: Ischemic Heart Disease. Chronic kidney Disease, stage 5 Angina pectoris, Acute myocardial infarction, Subsequent myocardial infarction, Certain current complications following acute myocardial infarction, Other acute ischaemic heart diseases, Chronic ischaemic heart disease,

Interventions

Intervention 1: Pentoxifylline Tab 400 mg daily 30 days in Intervention group. Intervention 2: Starch Tab daily in Control group.

Treatment - Drugs

Placebo

Pentoxifylline Tab 400 mg daily 30 days in Intervention group

Starch Tab daily in Control group

Eligibility

Sex/Gender

All

Age

15 Years to No maximum

Inclusion criteria

Inclusion criteria: Inclusion criteria: acceptance of written consent; End Stage Renal Disease; more than 15year; BMI between 15 - 35 Exclusion criteria: pentoxifylline use before study; no acceptance of written consent; abnormal LFT; hyper sensitivity reaction to pentoxifylline; active infection; recent malignancy; depression;recent ICH; recent retinal hemorrhage; dialysis period under 3 months

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
CRP. Timepoint: before and after receiving placebo or drug. Method of measurement: quantitative kit of CRP.	—

Secondary

Measure	Time frame
Dialysis Adequacy. Timepoint: before and after dialysis and before and after receiving placebo or drug. Method of measurement: KT/V: K ( cc/min ) x time ( min ) / urea volume ( cc ).	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Afsaneh Talayi

Amiralmomenin Hospital

amoozesh@arakmu.ac.ir+98 86 3417 3601

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026